MedPath

LOCAMETZ

These highlights do not include all the information needed to use LOCAMETZ safely and effectively. See full prescribing information for LOCAMETZ. LOCAMETZ (kit for the preparation of gallium Ga 68 gozetotide injection), for intravenous use Initial U.S. Approval: 2020

Approved
Approval ID

1ea62b65-8138-4a88-8a33-4060ececa42f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 8, 2023

Manufacturers
FDA

Advanced Accelerator Applications USA, Inc

DUNS: 051714355

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

kit for the preparation of gallium Ga 68 gozetotide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69488-017
Application NumberNDA215841
Product Classification
M
Marketing Category
C73594
G
Generic Name
kit for the preparation of gallium Ga 68 gozetotide
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateMarch 23, 2022
FDA Product Classification

INGREDIENTS (6)

SODIUM ACETATEInactive
Code: 4550K0SC9B
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
GENTISIC ACIDInactive
Code: VP36V95O3T
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
NITROGENInactive
Code: N762921K75
Classification: IACT
GOZETOTIDEActive
Quantity: 25 ug in 1 1
Code: 9AG41L3AOQ
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LOCAMETZ - FDA Drug Approval Details